MANNKIND CORPORATION
Last · NASDAQ$3.02-0.03 (-0.98%)close · yahoo · 16h ago
Vol 7.93M ≈ 23.96M
MA10MA20MA50
Market cap$971.06M321.5M sh
P/E · TTM-21.6fwd 23.7 · eps -0.14 · loss
Beta1.08vs S&P 500
Div yield0.00%annual · TTM
52w range
$2.23$6.51
Volume7.9Msession
Issuer
Legal nameMANNKIND CORPORATION
HQUnited States (US)
ListingUS MNKD
ISINUS56400P7069
SectorHealthcare
IndustryDrugs (Pharmaceutical)
SIC2834
CurrencyUSD
Entity registrysec:0000899460
CIK0000899460
Websitewww.mannkindcorp.com
Employees592
AddressMannKind Corp. 1 Casper Street 06810, Danbury +818 661 5000
| Revenue | $199.5M |
|---|---|
| Operating income | $-2.0M |
| Net income | $-35.7M |
| Free cash flow | $-30.7M |
| Operating margin | -1.0% |
| Net margin | -17.9% |
| Period | 2026 |
Loading chart…
Upcoming earnings
WED.4NOV
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
$0.00
Est. revenue
110.3M
Press & signals
- GlobeNewswire
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
- GlobeNewswire
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
- GlobeNewswire
MannKind Announces $50 Million Private Placement
Documents
FormReporting forFiledFlags
Showing 4 of 4 filings